Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

NCT07686796 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Local Advanced Rectal Cancer
PD-1 Inhibitor
PCSK9 Inhibitor
RCT
Radiotherapy
Capecitabine
Oxaliplatin

Interventions

RADIATION: Short-course radiotherapy
DRUG: CAPOX (oxaliplatin/capecitabine)
DRUG: Sintilimab
DRUG: Tafolecimab

Sponsor

Guangdong Provincial People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]